New York, New York, Jul 26, 2001 (Market News Publishing via COMTEX) -- Global Innovative Systems, Inc., a Nevada Corporation, announced that results of a double-blind, multi-site clinical trial of the Enermed device for the treatment of multiple sclerosis symptoms (MS) are being submitted for publication in a peer reviewed journal.

MS is a chronic, often disabling disease that randomly attacks the central nervous system. The potential relevance of the Enermed for MS was first demonstrated in a double-blind, placebo controlled pilot study conducted by Todd Richards, PhD., Professor of Radiology at the University of Washington. The Enermed treatment was associated with significant improvements on a composite measure of 8 common symptoms of MS. The results of this study were published in the peer reviewed Journal of Alternative and Complementary Medicine in 1997 (Richards et al., 1997, 3(1):21-29).

The encouraging results of the pilot study led to a $300,000 grant from the Multiple Sclerosis Association of America (MSAA) to further study the potential of this innovative therapy. The grant allowed the Company to complete a large-scale, double-blind, placebo controlled trial or the device at three sites around the country. This larger clinical trial was designed to see how extremely low frequency, pulsed electromagnetic fields (EMF's) affected three of the most common and debilitating symptoms of MS: fatigue, bladder control problems, and spasticity.

The "Enermed Therapy," is an innovative electrodeless technology that, prior to the pilot study with MS, was used primarily to treat migraine headaches. The technology allows a trained technician to take a reading of the amplitude or the bioelectromagnetic signals emitted by individual patients. The Enermed Device, a non invasive, pulsed electromagnetic field generator is then programmed based on each patient's own bioelectromagnetic profile. The electromagnetic energy generated by the Enermed is similar in strength to the electromagnetic field produced by the earth.

The 1997 pilot study and the more recent multi-site clinical trial of the Enermed demonstrate the Company's commitment to completing the research required for FDA approval of this therapy. A non-pharmacological treatment for the symptoms of MS would be a tremendous breakthrough for the MS community. It is estimated that 350,000 people in the United States and up to 2 million people worldwide suffer from MS. The National Multiple Sclerosis Society estimates that direct and indirect costs associated with MS exceed 9 billion dollars annually.

Certain of these statements contained in this press release may be deemed forward-looking statements. Such statements, and other matters addressed in this press release, involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from these statements and matters are the risks and other factors detailed, from time to time, in the Company's reports with Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form l0-Q.

On Enermed Therapy for symptomatic relief of MS and migraine headaches visit the Company's website at www.enermed.com